| |
 |
 |
NAME: Scott M. Hammer, MD
ACADEMIC TITLE:
Chief, Division of Infectious Diseases
Harold C. Neu Professor of Medicine
Professor of Epidemiology
|
EDUCATION:
Columbia College, BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972
SPECIALTY: HIV pathogenesis, therapy, and vaccine development
RESEARCH SUMMARY:
Dr Scott Hammer is the Harold C. Neu Professor of Medicine, professor of epidemiology, and chief of the Division of Infectious Diseases at the Columbia University Medical Center. He is also the program director for the Infectious Disease Fellowship at Columbia University Medical Center. His career has been devoted to improving the treatment of HIV infection. He has been an active investigator in the Adult AIDS Clinical Trials Group (AACTG) sponsored by the National Institute of Health (NIH). In the 1990s, he chaired the two largest antiretroviral trials of the AACTG, ACTG 175 and ACTG 320, which helped advance combination therapy as the standard of care worldwide. Dr Hammer is also an investigator in the NIH-sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the Protocol Chair for the Partnership for AIDS Vaccine Evaluation (PAVE) 100, a phase IIb clinical trial to evaluate the efficacy, safety, and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine followed by a multiclade recombinant adenoviral vector vaccine in HIV-uninfected persons. He currently is a member of the executive committee of the AACTG and is chair of the phase I/II committee of the HVTN. He has served as an adviser to the Swiss HIV Cohort Study, the French Agence Nationale de Recherches sur le SIDA (ANRS), and the HIV Netherlands–Australia–Thailand (NAT) Research Collaborative. He is vice chair of the IAS–USA Antiretroviral Guidelines Panel and editor in chief of the World Health Organization's (WHO) Antiretroviral Guidelines for Resource Limited Settings. He also serves as a member of the governing council of the International AIDS Society.
SELECTED PUBLICATIONS:
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.
Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.
Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.
Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.
Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.
Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.
Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.
Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM,
Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS,
Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki
B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM,
Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS,
Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.
Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.
Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM: The challenge of HIV-1 subtype diversity. NEJM 2008;358:1590-1602.
Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel. JAMA 2008; 300:555-570.
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 305-7185
Fax: (212) 305-7290
E-mail: smh48@columbia.edu
NAME: Karen Brudney, MD
ACADEMIC TITLE:
Assistant Clinical Professor of Medicine
EDUCATION:
Yale University, BA, 1973
Columbia University College of Physicians and Surgeons, MD, 1980
SPECIALTY: HIV pathogenesis, therapy, and vaccine development
RESEARCH SUMMARY:
Dr Brudney is the director of the Infectious Disease/AIDS Clinic and the director of TB service at NewYork–Presbyterian Hospital. She is also the program director for the Treatment Adherence Demonstration Project. In order to improve antiretroviral adherence in difficult populations, an interdisciplinary program called Jumpstart was initiated in 1998 in the Infectious Disease/AIDS Clinic at NewYork–Presbyterian Hospital. Results from this successful program are currently being analyzed. Dr Brudney is also the recipient of a Fogarty Award for AIDS International Training and Research to deliver HIV treatment and study the epidemiology of sexually transmitted diseases in Santo Domingo, Dominican Republic.
SELECTED PUBLICATIONS:
Brudney K, Dobkin JF. Resurgent tuberculosis in New York City: HIV homelessness and the decline of TB control programs. Am Rev Respir Dis. 1991;144:745-749.
Brudney K, Dobkin JF. A tale of two cities: TB control in Nicaragua and New York. Sem Resp Inf. 1991;6:261-272.
Brudney K. Homelessness and tuberculosis: A study in failure. J Law Med Eth. 1993;23:360-367.
Frieden TR et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: Epidemiology and clinical outcomes. JAMA. 1996;276:1229-1235.
Sackoff J et al. Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in NYC. AIDS. 1998;12:2017-2023.
Ellerbock TV et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to anti-retroviral therapy. J Infect Dis. 2004;190:1685-1691.
Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
Furuya EY, Paez A, Srinivasan A, Cooksey R, Augunbraun M, Baron M, Brudney K, Della-Latta P, Concepcion E, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV. “Outbreak of Mycobacterium abscessus wound infections among ‘Lipotourists’ from the United States who underwent abdominoplasty in the Dominican Republic.” Clinical Infectious Diseases 46:1181-8; 2008.
OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-7068
Fax: 212-305-7692
E-mail: Kfb2@columbia.edu
 |
|
NAME: Jay Dobkin, MD
ACADEMIC TITLE:
Arnold P. Gold Foundation Associate Professor of Clinical Medicine
|
EDUCATION:
Columbia College, BA, 1968
Dartmouth Medical School, BMS, 1970
Harvard Medical School, MD, 1972
SPECIALTY: Antiretroviral therapy, harm reduction
RESEARCH SUMMARY:
Dr Jay Dobkin is the Arnold P. Gold Foundation Associate Professor of Clinical Medicine. Dr Dobkin is the director of the AIDS program at Columbia University Medical Center. He is the principal investigator of an ongoing series of quantitative assessments of interventions to promote improved adherence to antiretroviral therapy. Dr Dobkin is also developing assessment strategies for antiretroviral treatment programs targeting injection drug users in the former Soviet Union in collaboration with several nongovernmental organizations active in these areas including the Open Society Institute (New York) and the Open Health Institute (Moscow). He serves as a consultant to the World Health Organization on care and treatment of HIV-infected injection drug users. He is involved in research examining the pathogenesis of HIV-associated bone loss in a longitudinal cohort of postmenopausal women. Dr Dobkin is also the principal investigator of several industry-sponsored studies of new antiretroviral agents.
SELECTED PUBLICATIONS:
Cohn D, Dobkin JF. Treatment and prevention of tuberculosis in HIV infection. AIDS. 1993;7(suppl 1):S195-S202.
Brunswick A et al. HIV-1 seroprevalence and risk behaviors in an urban African American community cohort. Am J Public Health. 1993;83:1390-1394.
Gormam JM et al. Development and characteristics of a medical staging system for HIV infection. Int J Methods Psychiatr Res. 1993;2:117-124.
Thomas C, Dobkin JF, Weinberger O. TAT-medicated transcellular activation of HIV-1 long terminal repeat directed gene expression by HIV-1 infected peripheral blood mononuclear cells. J Immunology. 1994;153:3831-3839.
Lutfey M et al. Independent origin of mono-rifampin-resistant mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med. 1996;153:837-840.
Simpson D et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial. Neurology. 1996;44:1254-1259.
Bangsberg D et al. Reduction in tuberculin skin-test conversions among medical house staff associated with improved tuberculosis infection control practices. Infect Control Hosp Epidemiol. 1998;18:566-570.
Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
Dobkin J. Preventing pneumococcal disease. AIDS Reader. 2006. 16(2):81-2
AIDS Read. 2006 Feb;16(2):81-2.
OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-8507
Fax: 212-305-7692
E-mail: Jfd2@columbia.edu
 |
|
NAME: David A. Fidock, PhD
ACADEMIC TITLE:
Associate Professor of Microbiology and Medicine
|
EDUCATION:
Adelaide University, South Australia B.Sc., 1986
University Paris VII, France, Ph.D., 1994
SPECIALTY:
Malaria drug resistance, chemotherapy, pathogenesis, cell development
RESEARCH SUMMARY:
A major focus of our group is to elucidate the molecular basis of chloroquine resistance (CQR). By genetic linkage and positional cloning, we earlier identified the pfcrt gene, located within a chromosomal segment tightly linked to CQR, which encodes a novel 10-transmembrane transporter located on the intra-erythrocytic parasite’s digestive vacuole. Using allelic exchange techniques, we recently proved that mutations in this gene, identified in drug resistant parasites from around the globe, are sufficient to confer CQR to CQ-sensitive parasites. Current work focuses on understanding the contribution of the individual mutations to CQR, determining their impact on parasite resistance to other antimalarials, and investigating the biochemical basis of CQR. We are also developing animal models to explore the role of pre-existing immunity on host clearance of drug-resistant infections. In collaboration with Dr. Myles Akabas at AECOM, we are also investigating the natural transport properties of pfcrt in heterologous cells. Other studies focus on defining the role of PfATPase6, pfmdr1 and pfnhe in contributing to parasite susceptibility to artemisinin, quinine and mefloquine.
We are also deeply involved in a major public/private partnership, funded by the Medicines for Malaria Venture and the NIH, and including GlaxoSmithKline and several academic partners, that aims to develop new antimalarial drugs that target fatty acid biosynthesis in the malaria parasite.
Another aspect of our research is to investigate the molecular basis of how parasitized erythrocytes bind to host endothelium, enabling them to avoid splenic clearance. A variant antigen family, PfEMP1, mediates this binding. We are investigating mechanisms of gene regulation that contribute to this switching of gene expression between different members of this family and exploring the genetic basis of endothelial receptor specificity.
The fourth area of research focuses on the digestive vacuole, the site of CQ action. Specifically, we are examining which ER or Golgi proteins are involved in protein trafficking to this compartment and using transfection and bio-informatic approaches to define sequence motifs that direct proteins to this site.
SELECTED PUBLICATIONS:
Sisowath C, Petersen I, Veiga IM, Martensson A, Premji Z, Bjorkman A, Fidock DA & Gil JP (2008). In vivo selection of P. falciparum parasites carrying the chloroquine-sensitive pfcrt K76 allele upon treatment with artemether-lumefantrine in Africa. J. Infect. Dis. (in press).
Fidock DA, Eastmasn RE, Ward SA & Meshnick SR (2008). Recent highlights in antimalarial drug resistance and chemotherapy research. Trends in Parasitol. (in press).
Lee MCS, Moura PA, Miller EA & Fidock DA (2008). Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif. Mol. Microbiol. 68: 1535-1546.
Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Collins FH & Duffy PE (2008). Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118: 1266-1276.
Lee MCS & Fidock DA (2008). Arresting malaria parasite egress from infected red blood cells. Nature Chem. Biol. 4: 161-162.
Ekland EH & Fidock DA (2007). Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opinion Microbiol. 10: 363-370.
Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC & Fidock DA (2007). In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282: 2494-504.
Nkrumah LN, Muhle RA, Moura PA, Ghosh P, Hatfull G, Jacobs Jr. WR & Fidock DA (2006). Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nature Methods 3: 615-21.
Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, Alakpa GE, Hughes RH, Ward SA, Krogstad DJ, Sidhu ABS & Fidock DA (2005). A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24: 2294-305.
Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu ABS, Bray PG, & Ward SA* (2004) Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol. Cell 15: 867-77. *Co-corresponding authors.
Fidock DA, Rosenthal PJ, Croft SL, Brun R & Nwaka S (2004). Antimalarial drug discovery: efficacy models for compound screening. Nature Rev. Drug Disc. 3: 509-20.
Sidhu ABS, Verdier-Pinard D & Fidock DA (2002). pfcrt mutations confer chloroquine resistance to Plasmodium falciparum malaria parasites. Science 298: 210-3
Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su X-z, Nomura T, Fidock DA, Wellems TE, and Plowe CV (2001). A molecular marker for chloroquine resistant falciparum malaria. New Engl. J. Med. 344:257-63.
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu ABS, Deitsch K, Su X-z, Wootton JC, Roepe PD & Wellems TE (2000). Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:681-71.
LABORATORY HOMEPAGE:
http://microbiology.columbia.edu/fidock
OFFICE INFORMATION:
Department of Medicine and Microbiology
Hammer Health Sciences Center Room 1502
701 West 168th Street
New York, NY 10032
Tel: (212) 305-0816
Fax: (212) 305-4038
Email: df2260@columbia.edu Back to top
________________________________________________________________
 |
|
NAME: Mary Flood, MD, PhD
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
|
EDUCATION:
Dominican College of Blauvelt, BS, 1968
New York University, PhD, 1976
Teachers College, Columbia University, MA, 1983
Columbia College of Physicians and Surgeons, MD, 1987
SPECIALTY: General infectious diseases, HIV primary care, travel medicine
RESEARCH SUMMARY:
With a background in cell biology and basic science research, Dr. Flood focuses on clinical infectious diseases. Her interests include general infectious diseases with a particular interest in HIV primary care, infections in immunocompromised patients, endocarditis and septic arthritis. Dr. Flood is also qualified to do travel recommendations and immunizations.
SELECTED PUBLICATIONS:
Flood MT. "Infectious Arthritis." In: Current Practice of Medicine. RC Bone MD ed. Current Medicine, Philadelphia 1996, VIII: 16.1-10.
Brunswick AF, Messeri PA, Dobkin J, Flood MT, Yang A. "Sibling homophily in HIV infection: biopsychosocial linkages in an urban African-American sample. NIDA Research Monograph 151, 1995
Blaner WS, Das Sr, Gouras P, Flood MT. "Hydrolysis of 11-cis and all-trans retinyl palmitate by homogenates of human retinal epithelial cells. J Biol Chem 262 (1987): 53-58.
Flood MT, Gouras P, Kjeldbye H. "Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest Ophthal Vis Sci 19 (1980): 1309-1320.
OFFICE INFORMATION:
NewYork–Presbyterian Hospital
161 Fort Washington Avenue
Irving Pavilion, Room 221
New York, NY 10032
Tel: 212-305-8039
Fax: 212-305-1754
E-mail: mtf2@columbia.edu
Back to top
 |
|
NAME: E. Yoko Furuya, MD, MS
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
|
EDUCATION:
Harvard University, BA, 1995
University of Pennsylvania School of Medicine, MD, 1999
Columbia University Mailman School of Public Health, MS (Epidemiology), 2006
SPECIALTY:Clinical research in hospital epidemiology, antimicrobial resistance, and community-associated methicillin-resistant Staphylococcus aureus
RESEARCH SUMMARY:
Dr E. Yoko Furuya is the assistant director of hospital epidemiology for NewYork–Presbyterian Hospital, Columbia University Medical Center. Her research interests are focused in the areas of hospital epidemiology and antimicrobial resistance. She is a coinvestigator with Dr Franklin Lowy on a CDC-funded study investigating the prevalence of and risk factors for community-associated methicillin-resistant Staphylococcus aureus in northern Manhattan. Other current projects include the evaluation of hospital-specific empiric antibiotic guidelines on antibiotic utilization and resistance and the creation of a computer assisted hospital infection control surveillance system, which is a joint project with Infectious Diseases, Epidemiology, and Biomedical Informatics.
SELECTED PUBLICATIONS:
Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections including cardiothoracic surgery and device implants. Curr Opin Pharmacol 3: 464-9, 2003.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ: Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemotherapy 54: 566-9, 2004.
Podwall D, Gupta R, Furuya EY, Sevigny J, Resor SR: Angiostrongylus cantonensis meningitis presenting with facial nerve palsy. J Neurol 10:1280-1, 2004.
Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nature Rev Microbiol 4: 36-45, 2006.
Cook H, Furuya EY, Larson E, Vasquez G, Lowy FD: Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44: 410-3, 2007.
Furuya EY, Cook HA, Lee M, Miller M, Larson E, Hyman S, Della-Latta P, Mendonca E, Lowy FD: Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment. Am J Infect Control 35: 359-66, 2007.
Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV: Outbreak of Mycobacterium abscessus wound infections in US lipotourists who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46: 1181-8, 2008.
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: eyf2002@columbia.edu Back to top
NAME: Peter Gordon, MD
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
EDUCATION:
SUNY at Stony Brook, BS, 1986
SUNY at Stony Brook, School of Medicine, MD, 1990
SPECIALTY: HIV primary care, HIV clinical trials, HIV/HCV coinfection
RESEARCH SUMMARY:
Dr Gordon is an assistant professor of clinical medicine in the Division of Infectious Diseases at CUMC and the medical director of the NewYork–Presbyterian System Select Health, an HIV Special Needs Plan (SNP). He is also a coinvestigator for the Adult AIDS Clinical Trials Unit at CUMC and a principal investigator for industry-sponsored studies of new antiretroviral agents.
OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-9396
Fax: 212-305-7692
E-mail: pgg2@columbia.edu
Back to top
 |
|
NAME: Rachel J. Gordon, MD, MPH
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
Assistant Professor of Clinical Epidemiology
|
EDUCATION:
Yale University, B.S., 1996
Vanderbilt University School of Medicine, M.D., 2000
Columbia University Mailman School of Public Health, M.P.H. 2004
SPECIALTY:Staphylococcal molecular epidemiology and pathogenesis
RESEARCH SUMMARY:
Dr Rachel Gordon is an instructor in clinical medicine in the Division of Infectious Diseases at the Columbia University Medical Center.
Her research interests include the molecular epidemiology of Staphylococcal colonization and disease as well as Staphylococcal pathogenesis.
In a past project, she described two major Staphylococcus aureus clonal types colonizing and infecting AIDS patients in a drug rehabilitation facility.
This research demonstrated instability of the mec element, which is responsible for methicillin-resistance. Currently, she is completing a double-blinded, randomized controlled trial of mupirocin vs. placebo in the same population to see if nasal carriage and infection with S. aureus can be reduced. Currently, Dr. Gordon is investigating the molecular epidemiology and pathogenesis of S. epidermidis in ventricular assist device-related infections. She is also interested in bacterial infections in drug users.
SELECTED PUBLICATIONS:
Cespedes, C., B. Said-Salim, M. Miller, S.H. Lo, B.N. Kreiswirth, R.J. Gordon , P. Vavagiakis, R.S. Klein, and F.D. Lowy FD. The clonality of Staphylococcus aureus nasal carriage. J. Infect. Dis. 2005;191(3):444-52.
Gordon, R.J., B. Quagliarello, C. Cespedes, M. Chung, H. de Lencastre, P. Vavagiakis, M. Miller, B. Zeller, and F.D. Lowy. A Molecular Epidemiological Analysis of 2 Staphylococcus aureus Clonal Types Colonizing and Infecting Patients with AIDS. Clin. Infect. Dis. 2005;40:1028-1036.
Gordon, R.J. and F.D. Lowy. Bacterial Infections in Drug Users. NEJM 2005; 353:1945-54.
Gordon, R.J., B. Quagliarello, and F.D. Lowy. Ventricular assist device-related infections. Lancet Infect. Dis. 2006; 6:426-37.
Gordon, R.J. and F.D. Lowy. Pathogenesis of Methicillin-Resistant Staphylococcus aureus Infection. Clinical Infectious Diseases 2008; 46:S350-9.
ABSTRACTS
Jankolovits, R., B. Quagliarello, C. Cespedes, M. Miller, M. Chung, H. De Lencastre, B. Zeller, J. Justman, and F.D. Lowy. Two clonal types of Staphylococcus aureus dominate infection and nasal colonization in a NYC AIDS and drug treatment facility. Slide presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September, 2002.
Gordon, R. J., T. Martens, R. Wang, Y. Naka, B. Scully, E. Blumberg, and F. Lowy. Diagnostic Criteria for Diagnosing Ventricular Assist Device-Related Infections. Poster presentation at the 46th ICAAC, September, 2006.
R. Gordon, M. Bhat, C. Fairchild, J. Choe, U. Rawiel, D. Ascheim, M. Slaughter, Y. Naka, F. Lowy. Ventricular Assist Device Recipients Share Commensal S. epidermidis Clones and are Infected with Colonizing Strains. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.
R. Gordon, N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, M. Lee, P. Vavagiakis, F. Lowy. Monthly mupirocin decreases S. aureus nasal colonization in HIV/AIDS patients. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Phone: (212) 342-0109
Fax (212) 305-5794
E-mail: rj216@columbia.edu Back to top
 |
|
NAME: Jessica Justman, MD
ACADEMIC TITLE:
Assistant Professor of Clinical Epidemiology and Medicine
|
EDUCATION:
Yale University, BS, 1981
University of Rochester, MD, 1985
SPECIALTY: HIV primary care, antiretroviral therapy, metabolic complications
RESEARCH SUMMARY:
Dr Justman is the associate director of the Center for Infectious Disease Epidemiologic Research (CIDER). In addition, within the International Center for AIDS Care and Treatment Programs (ICAP), she is director of the University Technical Assistance program. Both CIDER and ICAP are part of the Mailman School of Public Health, Columbia University. Dr Justman's research interests are in the areas of microbicides and the metabolic complications of antiretroviral agents. Within the NIAID-funded HIV Prevention Trials Network (HPTN), she served as the principal investigator of the Bronx–Lebanon HPTN site, and conducted two phase I safety of vaginal microbicides in both HIV-infected and uninfected women and couples. Dr Justman is a cochair of HPTN 059, a phase II extended safety microbicide study which will enroll 200 women. She has worked with the NIAID-funded Women's Interagency HIV Study (WIHS) and has several publications on metabolic complications in this cohort. She also serves as vice chair of the New York State AIDS Institute's Medical Care Criteria Committee.
SELECTED PUBLICATIONS:
Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Eobinson E, Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH, Young M, Rubin N, Augenbraun M, Grunfeld C. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003;5:461-466.
Mulligan K, Anasos K, Justman J, Freeman R, Wichienkuer P, Robison E, Hessol NA. Fat distribution in HIV-infected women in the United States: DEXA substudy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2005;38:18-22.
Danoff A, Shi Q, Justman J, Mulligan K, Hessol N, Robison E, Lu D, Williams T, Wichienkuer P, Anaasotos K. Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. Acquir Immune Defic Syndr. 2005;39:55-62.
Tien PC, Schneider MF, Cole SR, Justman JE, French AL, Young M, DeHovitz J, Nathwani N, Brown TT. Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr. 2007. 44(1):43-8.
Watts DH, Springer G, Minkoff H, Hillier SL, Jacobson L, Moxley M, Justman J, Cejtin H, O’Connell C, Greenblatt RM. The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr. 2006. 43(2):161-8.
El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Masse B, Soto-Torres L, Kwiecien A. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006. 20(8):1109-16.
Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006. 20(4):543-51.
OFFICE INFORMATION:
722 W 168th Street, Room 714
Columbia University Medical Center
New York, New York 10032
Tel: 212-342-0537
E-mail: jj2158@columbia.edu Back to top
 |
|
NAME: Christine J. Kubin, PharmD, BCPS
ACADEMIC TITLE:
Assistant in Medicine
|
EDUCATION:
University of North Carolina at Chapel Hill, PharmD, 1998
SPECIALTY: Anti-infective pharmacology and therapeutics, antimicrobial resistance and epidemiology, antifungal therapy
RESEARCH SUMMARY:
Dr Kubin is the clinical pharmacy manager in the Division of Infectious Diseases at NewYork–Presbyterian Hospital, Columbia University Medical Center and a board-certified pharmacotherapy specialist. Her research interests focus on anti-infective treatment outcomes and the epidemiology of multi-drug resistant pathogens. Dr Kubin is a member of the joint Anti-Infective Subcommittee at NewYork–Presbyterian Hospital and co-spearheads antimicrobial stewardship activities with Dr. Furuya. Current projects include evaluating treatment outcomes and therapies for infections caused by carbapenem-resistant organisms, evaluating the relationships of antibiotic utilization and resistance within the hospital, and creating microbiology and antibiotic utilization components of the computer-assisted hospital infection control surveillance system currently in development.
SELECTED ABSTRACTS AND PUBLICATIONS:
Zeana C, Kubin CJ, Della-Latta P, Hammer S. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature. Clin Infect Dis. 2001 Aug 15;33(4):477-482.
Kubin CJ. Antimicrobial control programs. Semin Perinatol. 2002 Oct;26(5):379-386.
Sobieszczyk ME, Kubin CJ, Della-Latta P, Scully B. Antimicrobial use and rate of vancomycin-resistant Enterococcus infections in neutropenic patients on a hematology/oncology unit. Abstract presented at: 41st Annual Meeting of the Infectious Diseases Society of America; October 9-12, 2003; San Diego, CA.
Furuya EY, Sobieszczyk ME, Kubin CJ, Hay CM. Intraventricular polymyxin B for the treatment of multi-drug resistant gram-negative bacillary ventriculitis: Two successful cases. Abstract presented at: 41st Annual Meeting of the Infectious Diseases Society of America; October 9-12, 2003; San Diego, CA.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multi-drug resistant gram-negative respiratory tract infections. J Antimicrob Chemoth. 2004 Aug;54(2):566-569.
Hammer S, Kubin CJ. Antiretroviral Agents. In: Cohen J, Powderly WG, eds. Infectious Diseases, 2nd ed. Spain: Elsevier Limited; 2004:1871-1893.
Furuya EY, Kubin CJ, Yin MT, Lowy FD, Della-Latta P, Hammer SM. Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia. Abstract presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
Kubin CJ, Lam S, Hammer SM, Della-Latta P, Yin MT. Impact of caspofungin compared to fluconazole and lipid amphotericin B on outcomes in patients with candidemia. Abstract presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
Kubin CJ, Dzierba A. The effects of continuous renal replacement therapy (CRRT) on anti-infective therapy in the critically ill. J Oncol Pharm Pract. 2005;18:109-117.
Wong KK, Kubin CJ, Furuya EY. Characterization of Carbapenem-Resistant Klebsiella pneumoniae and Comparison with Carbapenem-Susceptible Klebsiella pneumoniae in Bacteremias. Abstract presented at: Annual Meeting of the Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA.
Hu J, Yin MT, Furuya Y, Eschenauer G, Hartman B, Hammer SM, Lowy FD, Kubin CJ. Outcomes in Patients Receiving Tigecycline for Infections due to Multi-drug Resistant Gram-Negative Organisms. Abstract presented at: 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL.
Patel SJ, Larson EL, Kubin CJ, Saiman L. A Review of Antimicrobial Control Strategies in Hospitalized and Ambulatory Pediatric Populations. Pediatr Infect Dis J 2007; 26(6):531-537.
Kubin CJ. Antimicrobial Stewardship Programs: Role in Optimizing Infectious Disease Outcomes. Disease Management and Health Outcomes 2008; (in press).
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: cck27@columbia.edu Back to top
 |
|
NAME: Franklin Lowy, MD
ACADEMIC TITLE:
Professor of Medicine and Pathology
|
EDUCATION:
Columbia College BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972
SPECIALTY: Internal Medicine and Infectious Diseases
RESEARCH SUMMARY:
Dr Franklin Lowy is a professor of medicine and pathology in the Division of Infectious Diseases in the College of Physicians and Surgeons at Columbia University. Dr Lowy's laboratory currently investigates the pathogenesis and epidemiology of Staphylococcus aureus and Staphylococcus epidermidis infections.
Studies on the pathogenesis of staphylococcal infections:
One area of research his an investigation of the pathogenesis of staphylococcal infections in patients with left ventricular assist devices (LVADs). The laboratory is investigating the role of different S. aureus and S. epidermidis surface proteins as mediators of adherence to explanted LVAD material. The goal is to identify potential vaccine candidates. A multi-center observational trial is also part of this project. The goal is to better understand the epidemiology of LVAD-related infections.
A second laboratory-based project is an investigation of the pathogenesis of community-associated methicillin-resistant S. aureus pneumonia. This invasive infection has accounted for increasing morbidity and mortality on the past few years. A mouse post-influenza model for S. aureus pneumoniahas been developed to determine which bacterial genes are unregulated during infections.
Studies on the transmission of S. aureus among high-risk populations:
Dr. Lowy’s group is conducting studies on the transmission of S. aureus among high risk populations including injecting and inhalation drug users in Bedford Stuyvesant, Brooklyn, in New York State Prisons, and in the Dominican population of Northern Manhattan. The goal of these studies is to gain a better understanding of the factors that contribute to the dissemination of S. aureus among the high risk groups.
SELECTED PUBLICATIONS:
Lowy FD. Staphylococcus aureus Infections. N Engl J Med. 1998;339:520-532.
Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest. 2003;111:1265-1273.
Cespedes C et al. The clonality of Staphylococcus aureus nasal carriage. J Infect Dis. 2005;191:444-452.
Gordon RJ et al. A molecular epidemiological analysis of 2 Staphylococcus aureus conal types colonizing and infecting patients with AIDS. Clin Infect Dis. 2005;40:1028-1036.
Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353:1945-1954.
Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nature Microbiol Rev. 2006;4:36-45.
Arrecubieta C, Asai T, Bayern M, Loughman A., Fitzgerald J Ross, Shelton CE, Baron HM, Dang NC, Deng M, Naka Y, Foster TJ, and Lowy FD. The role of S. aureus adhesions in the pathogenesis of ventricular assist device related infections. J Infect Dis. 2006;193:1109-1119.
Aiello AE, Lowy FD, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis. 2006;6:335-41.
Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis. 2006;6:426-37.
Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:410-3.
Lowy, F.D., Aiello, A.E., Bhat, M., Johnson-Lawrence, V.D., Lee, M., Burrell, E., Wright, L.N., Vasquez, G. and Larson, E.L. Staphylococcus aureus colonization and infection in New York State Prisons. J. Infect. Dis. 196:911-918, 2007.
Arrecubieta, C., Lee, M., Macey, A., Foster, T.J. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, binds type 1 collagen. J. Biol. Chem. 282:18767-18776, 2007.
Lowy, F. D. Secrets of a superbug. Nat. Med.13:1418-1420, 2007.
Gordon, R. and Lowy, F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46:5350-359, 2008.
Lowy, F.D. Staphylococcal Infections In: Harrison’s Principles of Internal Medicine, 17th edition. Editors: A. S. Fauci, E. Braunwald, D.L. Casper, S. L. Hauser, D. L. Longo, J. L. Jameson and J. Loscalzo. The McGraw- Hill Companies, Inc., p.872-881, 2008.
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, 9-458
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-5794
E-mail: fl189@columbia.edu Back to top
 |
|
NAME: Ellen Morrison, MD, MPH
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine and Clinical Epidemiology
|
EDUCATION:
Olivet Nazarene College, BA, 1979
Washington University School of Medicine, MD, 1984
Columbia University Mailman School of Public Health, MPH, 1996
SPECIALTY: General infectious diseases, HIV/AIDS, sexually transmitted diseases, infections in pregnancy
RESEARCH SUMMARY:
Dr Morrison is an assistant professor of clinical medicine in the Division of Infectious Diseases. She is the program director for the Nicholas A. Rango HIV Scholar's program at NewYork–Presbyterian Hospital. Dr Morrison is also the medical director of the HIV Counseling and Testing Service at NewYork–Presbyterian Hospital.
SELECTED PUBLICATIONS:
Morrison EAB et al. Human papillomavirus infection and other risk factors for cervical neoplasia: A case control study. Int J Cancer. 1991;49:6-13.
Morrison EAB et al. Self-administered home cervicovaginal lavage: A novel tool for the clinical/epidemiological investigation of genital HPV Infections. Am J Obstet Gynecol. 1992;167:104-107.
Morrison EAB et al. Quantitation may improve clinical utility. J Clin Micro. 1992;30:2539-2543.
Morrison EAB et al. Pregnancy and cervical infection with human papillomaviruses. Int J Gyn Obstet. 1996;54:125-130.
Morrison EAB et al. Low prevalence of cervical human papillomavirus infection in renal transplant recipients. Neph Dial Trans. 1996:1603-1606.
Morrison EAB et al. Development of a multi-item scale to quantitatively assess sexual behaviors and the transmission of high and low risk human papillomaviruses. Sex Trans Dis. 1998;25:509-515.
Morrison EAB and Levenson J. Medical Treatment and Occupational Exposure. In: Fernandez F and Ruiz P, eds. Psychiatric Aspects of HIV/AIDS. Philadelphia: Lippincott Williams and Wilkins; 2006:23-35.
OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-6328
E-mail: eam6@columbia.edu Back to top
 |
|
NAME: Susan Olender, MD
ACADEMIC TITLE:
Instructor in Clinical Medicine
|
EDUCATION:
SUNY at Albany, BA, 1994
NYU School of Medicine, MD, 2002
SPECIALTY: HIV primary care
SELECTED PUBLICATIONS:
Olender S, Saito M, Apgar J, et al. "Low prevalence and increased household clustering of Mycobacterium tuberculosis infection in high altitude villages in Peru" Am J Trop Med Hyg. 2003 Jun;68(6):721-7.
Chiasson MA, Massad LS, Olender S, Wright TC. HIV Infection in Women in Atlas of AIDS. Mandell GL and Mildvan D editors, Fourth Edition. Current Medicine, 2007.
Wilkin TJ, Taylor B, Olender S, Hammer SM. "Advances in Antiretroviral Therapy." Topics in HIV Medicine, 2008; 16:31-60. http://www.iasusa.org/pub/topics/2008/issue1/31.pdf
Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. AIDS, 2008; 22(8):947-55.
OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-3174
Fax: 212-305-7692
E-mail: so2045@columbia.edu Back to top
 |
|
NAME: Brian Scully, MD
ACADEMIC TITLE:
Associate Professor of Clinical Medicine
|
EDUCATION:
Trinity College, Dublin University, BA, 1969
Trinity College, Dublin University, MB, BCh, BAO, 1971
Trinity College, Dublin University, MA, 1973
SPECIALTY: Nosocomial infections, transplant infectious disease
RESEARCH SUMMARY:
Dr Scully is the chair of the Infection Control Committee at NewYork–Presbyterian Hospital, and cochair of the Joint Infection Control Committee and the Joint Subcommittee on Anti-infective Use. His research interests are in nosocomial infections, transplant infectious disease, and hospital epidemiology.
SELECTED PUBLICATIONS:
Argenziano et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant. 1997;16:822-831.
Sinha et al. Infections during left ventricular assist device support do not affect postransplant outcomes. Circulation. 2000;102III:194-199.
Knirsh CA et al. An outbreak of Legionella micdadei pneumonia in transplant patients: Evaluation, molecular epidemiology, and control. Am J Med. 2000;108:290-295.
Saiman L et al. Banning artificial nails from health care settings. Am J Infect Control. 2002;11:252-254.
Lux JZ et al. Transfusion-associated babesiosis after heart transplant. Emerg Infect Dis. 2003;9:116-119.
Haas S, Scully B, Cohen D, Radhakrishnan J. Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis. 2005 7(2):75-9.
Farr M, Rubin AI, Mangurian C, Scully B et al. Late syphilis in cardiac transplant patient. J Heart Lung Transplant. 2006 25(3): 358-61.
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290 Back to top
 |
|
NAME: Magdalena Sobieszczyk, MD, MPH
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
|
EDUCATION:
Harvard University, BA, 1994
Columbia College of Physicians and Surgeons, MD, 1998
Columbia University Mailman School of Public Health, MPH, 2006
SPECIALTY: HIV vaccine trials, international HIV, metabolic complications of HIV therapy
RESEARCH SUMMARY:
Dr. Magdalena Sobieszczyk is an Assistant Professor of Clinical Medicine in the Infectious Diseases Division at the Columbia University College of Physicians. Her current research experience includes complications of antiretroviral therapy, and HIV vaccines. Under the auspices of the Center for Infectious Disease Epidemiologic Research (CIDER), she is collaborating with Dr. Jessica Justman at the Mailman School of Public Health to study the prevalence of the metabolic syndrome and its association with inflammatory markers among HIV-infected women in The Women’s Interagency HIV Study (WIHS) cohort. She is a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled “Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection” (Salim Abdool Karim, PI). Dr. Sobieszczyk is also a co-PI for a study evaluating the prevalence of insulin resistance among HIV-1 negative and recently infected South African women in the Acute Infection Study cohort.
She is a co-investigator for the New York HIV Vaccine Trials Unit at Columbia University and the New York Blood Center and is involved in developing and chairing a national and international HIV vaccine protocol.
SELECTED ABSTRACTS AND PUBLICATIONS:
Sobieszczyk ME, Kubin CJ, Della-Latta P, Scully B. Antimicrobial use and rate of Vancomycin-resistant Enterococcus infections in neutropenic patients on a Hematology- Oncology unit. Abstract presented at the 41st Annual Meeting of the Infectious Diseases Society of America. October 2003.
Furuya EY, Sobieszczyk ME, Kubin CJ, Hay CM. Intraventricular Polymyxin B for the treatment of multi-drug resistant Gram-negative bacillary ventriculitis: Two successful cases. Abstract presented at the 41st Annual Meeting of the Infectious Diseases Society of America. October 2003.
Sobieszczyk ME, Furuya EY, Kubin CJ, Hay CM. Efficacy and safety of Polymyxin B in the treatment of infections caused by multi-drug resistant Gram-negative organisms. Journal of Antimicrobial Chemotherapy. 2004 Aug; 54(2):566-9.
Sobieszczyk ME, Hay CM. “Gender-Specific Issues in Non-HIV Viral Infections” in Principles of Gender Specific Medicine. Edited by Marianne J. Lagato
Academic Press May 2004.
Sobieszczyk ME, Coakley EP, Wilkin TJ, Hammer, SM. Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004.
Topics in HIV Medicine. 2004 Mar-Apr;12(1):9-2
Mariller MM, Abramson D, Sobieszczyk ME. The Validity of Self-Reported Clinical Markers and Medication Regimens: A Pilot Study. CHAIN Report 2004-6. Submitted Nov 17, 2004.
Sobieszczyk ME, Talley AK, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Highlights of the 12th Conference on Retroviruses and Opportunistic Infections, 2005. Topics in HIV Medicine. 2005 Mar-April; 13(1):22-44.
Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Highlights of the 13th Conference on Retroviruses and Opportunistic Infections, 2006. Topics in HIV M edicine. 2006 April; 14(1):22-44.
Sobieszczyk ME, D.R. Hoover, K. Anastos, K. Mulligan, T. Tan, C. Hyman, M.H. Cohen, S.R. Cole, J. Justman, Women's Interagency HIV Study. Prevalence and predictors of metabolic syndrome among HIV-positive and negative women. J Acquir Immune Defic Syndr, 2008; 48:272-280
Sobieszczyk ME, Taylor B, Hammer SM. Antiretroviral Agents. In Clinical Virology, Richman Whitley, Hayden, Third Edition, 2008.
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The Challenge of HIV-1 Subtype Diversity. New England Journal of Medicine, 2008; 358:1590-1602
Mlisana K, Auld SC, Grobler A, van Loggerenberg F, Williamson C, Iriogbe I, Sobieszczyk ME, Abdool Karim SS; CAPRISA Acute Infection Study Team. Anaemia in acute HIV-1 subtype C infection. PLOS One, 2008; 3(2):e1626
K. Mlisana, A. Feinstein, M. Sobieszczyk, L. Werner, C. Williamson, F. Van Loggerenberg, S. Abdool Karim, CAPRISA 002 Acute HIV Infection Study Team. Clinical signs and symptoms of Aacute HIV subtype C infection among South African women. AIDS 2008 - XVII International AIDS Conference
Abstract no. THPE0084. Manuscript in progress
M. Sobieszczyk, K. Mlisana, A. Feinstein, L. Werner, S. Auld, C. Williamson, F. Van Loggerenberg, S. Abdool Karim, CAPRISA 002 Acute HIV Infection Study Team3.
Metabolic syndrome in acutely HIV-infected South African women. AIDS 2008 - XVII International AIDS Conference
Abstract no. THPE0088. Manuscript in progress
OFFICE INFORMATION:
630 W 168th Street, Box 82
Columbia University Medical Center
New York, New York 10032
Tel: 212-305-7185
E-mail: mes52@columbia.edu
Back to top
 |
|
NAME: Simon Tsiouris, MD, MPH
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine and Clinical Epidemiology
|
EDUCATION:
Johns Hopkins University School of Arts and Sciences, BA, 1994
Johns Hopkins University School of Medicine, MD, 1998
Columbia University Mailman School of Public Health, MPH, 2004
SPECIALTY: TB and TB/HIV epidemiology, TB diagnostics
RESEARCH SUMMARY:
Dr. Simon Tsiouris is assistant professor of clinical medicine and clinical epidemiology at the Columbia University Medical Center and assistant attending in infectious diseases at the New York–Presbyterian Hospital. Dr Tsiouris's research interests include TB and HIV epidemiology, TB diagnostics, and TB/HIV operational research. He has conducted a latent TB infection survey of schoolchildren in a South African township and he has been involved in a similar survey in Peru. His work in South Africa has included the evaluation of the sensitivity of a TB-specific whole blood interferon-gamma release assay. Dr. Tsiouris is co-investigator on a CDC Tuberculosis Epidemiologic Studies Consortium-sponsored multi-site study to evaluate new interferon-gamma release assays in the diagnosis of LTBI in health care workers. He is also co-investigator on the NIH sponsored East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) study. Dr. Tsiouris is also involved in an ongoing study of the diagnosis of TB and LTBI in children in Thailand.
SELECTED PUBLICATIONS:
El-Sadr WM and Tsiouris SJ*. HIV-Associated Tuberculosis: Diagnostic and Treatment Challenges. Seminars in Respiratory and Critical Care Medicine. 2008; 29(5): 525-531 *Corresponding author
M Gasana, G Vandebriel, G Kabanda, SJ Tsiouris*, J Justman, R Sahabo, D Kamugundu, W El-Sadr. Integrating Tuberculosis and HIV care in rural Rwanda. International Journal of Tuberculosis and Lung Disease.2008; 12(3):S39–S43. *Corresponding author
Gasana M, Vandebriel G, Kabanda G, Mugabo J, Tsiouris SJ, Ayaba A, Finlay A, Justman J, Sahabo R, El-Sadr W. Tuberculosis in Rwanda: Challenges to reaching the targets. Bulletin of the World Health Organization: Special theme: Tuberculosis control. 2007; 85(5):383-384.
SJ Tsiouris, NR Gandhi, WM. El-Sadr, G Friedland. Tuberculosis and HIV, Needed: A New Paradigm for the Control and Management of Linked Epidemics. eJournal of the International AIDS Society Medscape General Medicine. 2007;9(3):62. Posted 09/25/2007. Available at: http://www.medscape.com/viewarticle/561367
Y Hirsch-Moverman, S Tsiouris, J Salazar-Schicchi, PW Colson, H Muttana, W El-Sadr. Physician Attitudes Regarding Latent Tuberculosis Infection: International vs. U.S. Medical Graduates. International Journal of Tuberculosis and Lung Disease.2006;10(10):1178–1180.
SJ Tsiouris, D Coetzee, PL Toro, J Austin, Z Stein, W El-Sadr. Sensitivity Analysis and Potential Uses of a Novel Gamma Interferon Release Assay for Diagnosis of Tuberculosis. Journal of Clinical Microbiology. 2006;44(8):2844-2850.
SJ Tsiouris, J Austin, P Toro, D Coetzee, K Weyer, Z Stein, W El-Sadr. Results of a tuberculosis-specific IFN-γ assay in children at high risk for tuberculosis infection. International Journal of Tuberculosis and Lung Disease. 2006; 10(8):939-941.
M Saito, W Pan, R Gilman, C Bautista, S Bamrah, C Martin, S Tsiouris, DF rguello, G Martinez-Carrasco. Comparison of altitude effect on Mycobacterium tuberculosis infection between rural and urban communities in Peru. American Journal of Tropical Medicine & Hygiene. 2006; 75(1): 49–54.
Tsiouris S, Lowy FD. “Gender and Bacterial Infections” in Principles and Practices of Gender Specific Medicine. 1st ed., Legato MJ, editor. Academic Press, San Diego 2004.
Tsiouris SJ, Breschel TS, Xu J, McInnis MG, McMahon FJ. Linkage disequilibrium analysis of G-olf alpha (GNAL) in bipolar affective disorder. American Journal of Medical Genetics. 1996 Sep 20; 67(5):491-4.
SELECTED ABSTRACTS:
Gasana M, Vandebriel G, Gaspard K, Tsiouris S. Integrating Tuberculosis and HIV Care in Rwanda, Oral presentation, the President’s Emergency Plan for AIDS Relief Third Annual Field Meeting, 2006, Durban.
Vandebriel G, El-Sadr W, Gasana M, Justman J, Koscelnik V, Tsiouris S. Increasing collaboration and integration between TB and HIV programs and services in Rwanda. Oral presentation, the President’s Emergency Plan for AIDS Relief Second Annual Field Meeting, 2005, Addis Ababa
OFFICE INFORMATION:
630 W 168th Street, Box 82
Columbia University Medical Center
New York, New York 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: st326@columbia.edu
Back to top
 |
|
NAME: Michael Yin, MD, MS
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
|
EDUCATION:
Princeton University, BA, 1991
Columbia College of Physicians and Surgeons, MD, 1996
Columbia University Mailman School of Public Health, MS (Epidemiology), 2004
SPECIALTY: HIV therapy and metabolic complications
RESEARCH SUMMARY:
Dr Yin is an assistant professor of clinical medicine in the Division of Infectious Diseases. Dr Yin's primary research interest is in the metabolic complications of HIV infection and antiretroviral therapy. With support from an NIH/NIAID K23 research career award, he is examining the pathogenesis of HIV-associated bone loss in women utilizing novel molecular assays and bone histomorphometry. He is a member of the NIH-sponsored Women’s Health Interagency Study (WIHS) Metabolic Working Group, and is the lead investigator for several bone metabolism related analyses. He is also a site investigator in the AIDS Clinical Trials Unit and the HIV Vaccine Trials Unit at Columbia University Medical Center.
SELECTED PUBLICATIONS:
Yin M, Despommier D. Gender and parasitic infections. In: Legato,MJ, ed. Principles and Practices of Gender-Specific Medicine. 1st ed. San Diego, CA: Academic Press; 2004.
Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV infected postmenopausal women. Osteoporosis International, 2005; 16(11):1345-52
Yin MT, Glesby M. Recombinant human growth hormone (somatropin) therapy in HIV-associated wasting and visceral adiposity. Expert Review in Anti-Infective Therapy, 2005; 3(5): 727-38
Yin MT, Glesby M. Low Bone Mineral Density, HIV, and Women: Fracture or Fiction? Clinical Infectious Diseases, 2006; 42(7):1021-3.
Yin MT, Shane E. Low bone mineral density in patients with HIV: pathogenesis and clinical significance. Current Opinion in Endocrinology and Diabetes, 2006; 13:497-502
Yin MT, Dobkin J, Grbric J. HIV Infection and Associated Periodontal Manifestations. Periodontology 2000, 2007; 44: 1-27.
OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: mty4@columbia.edu Back to top
 |
|
NAME: Mary Ann Chiasson, MS, MPH, DrPH
ACADEMIC TITLE:
Associate Professor of Clinical Epidemiology (in Medicine)
|
EDUCATION:
Bennington College, BA, 1972
New York University, MS, 1978
Columbia University Mailman School of Public Health, MPH, 1985
Columbia University Mailman School of Public Health, DrPH, 1988
SPECIALTY: Epidemiology of HIV, HPV, and other STIs; reproductive health
RESEARCH SUMMARY:
Dr Mary Ann Chiasson is an epidemiologist with a part-time faculty appointment in the Division of Infectious Diseases. Her primary appointment is in the Epidemiology Division at Columbia's Mailman School of Public Health where she directed the Epidemiology of HIV/AIDS course from 1989 through 2003. Dr Chiasson has been the vice president for research and evaluation at Public Health Solutions since 1999. Before joining Public Health Soluti ons, she served for nine years as an assistant commissioner of health at the New York City Department of Health with scientific and administrative responsibility for AIDS surveillance, HIV/AIDS research and vital statistics, and epidemiology. Dr Chiasson's research interests include the epidemiology of HIV (particularly risk factors for sexual transmission and gynecologic manifestations of HIV), women's reproductive health, and infant mortality. Her current research focuses on the role of the Internet in increasing high risk sexual behavior among men who have sex with men. The online HIV prevention videos produced by the research collaboration she leads can be viewed at www.hivbigdeal.org.
SELECTED PUBLICATIONS:
Sun X-W, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica BA Hamburg MA. Declining HIV/AIDS mortality in New York City. JAIDS.1999;21:59-64.
Ellerbrock TV, Chiasson MA, Bush TJ, Sun X-W, Sawo D, Brudney K, Wright TC. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
Chiasson MA, Parsons JT, Tesoriero JM, Carballo-Dieguez A, Hirshfield S, Remien RH. HIV behavioral research online. J Urban Health 2006; 83:73-85.
Aidala AA, Lee G, Garbers S, Chiasson MA. Sexual behavior and sexual risk in a prospective cohort of HIV-positive men and women in New York City, 1994-2002: Implications for prevention. AIDS Educ Prev 2006; 18:12-32.
Chiasson MA, Hirshfield S, Remien RH, Humberstone M, Wong T, Wolitski RJ. A comparison of online and offline sexual risk in men who have sex with men: An event-based online survey 2006. JAIDS in press.
OFFICE INFORMATION:
Public Health Solutions
220 Church Street, 5th floor
New York, NY 10013
Tel: 646-619-6411
Fax: 646-619-6777 Back to top
NAME: Alan Dunn, MD
ACADEMIC TITLE:
Assistant Clinical Professor of Medicine
EDUCATION:
New York University, 1967
New York Medical College, MD, 1971
SPECIALTY: Sexually transmitted diseases
OFFICE INFORMATION:
New York City Department of Health
Sexually Transmitted Disease Program
160 West 100th Street, Room 146
New York, NY 10025
Tel: 212-865-1951
E-mail: adunn@health.nyc.gov Back to top
 |
|
NAME: Christine Hogan, MD
ACADEMIC TITLE:
Assistant Professor of Clinical Medicine
|
SPECIALTY: Acute and recent HIV-1 infection
RESEARCH SUMMARY:
Christine Hogan is an assistant professor in the Division of Infectious Diseases at Columbia University Medical Center. She is a subinvestigator in the AACTG, contributing to clinical trials of HIV therapeutics. She also leads CUMC's Acute HIV Infection program, the purpose of which is to identify persons with acute or recent HIV-1 infection, engage them in comprehensive HIV care, and invite them to participate in clinical trials. The clinical trials are part of the NIH-funded Acute Infection and Early Disease Research Program (AIEDRP), a multisite pathogenesis and clinical trials network in which Columbia participates. Dr Hogan is the national protocol chair of a multisite protocol of treatment during early HIV-1 infection which is being performed within the AACTG as well as AIEDRP. Dr Hogan follows a panel of patients longitudinally in the department's HIV clinic and precepts ID fellows during their outpatient clinic experience. She is the course director for Microbiology/Infectious Diseases, the second-year medical student course in infectious diseases at Columbia University.
SELECTED PUBLICATIONS:
Hogan C, Hammer S. Host determinants in HIV infection and disease Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.
Hogan C, Hammer S. Host determinants in HIV infection and disease Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.
Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson A, Ho D, Markowitz M. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896-900.
Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M, Perelson A, Markowitz M. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naïve chronically HIV-1-infected individuals. AIDS. 2003;17:1151-1156.
Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770.
Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol. 2004;78:14039-14042.
OFFICE INFORMATION:
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: ch358@columbia.edu Back to top
_________________________________________________________________
 |
NAME: Charles Knirsch, MD, MPH
ACADEMIC TITLE:
Adjunct Assistant Professor of Medicine |
EDUCATION:
McGill University, BSc, 1981
McGill University, MD, 1985
Columbia University, MPH, 1995
SPECIALTY: TB, travel medicine
RESEARCH SUMMARY:
Charles Knirsch, MD, MPH research has integrated work with several Public-Private-Partnerships to collaborate on disease control and elimination programs. This has involved work on addressing information management for tuberculosis patient treatment protocols and hospital epidemiology in New York to more recent international sector collaborations on malaria with The National Institutes of Health and The Centers for Disease Control and Prevention. Chuck currently collaborates with The World Health Organization and The International Trachoma Initiative on a program to eliminate blinding trachoma by the year 2020.
SELECTED PUBLICATIONS:
Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Noncompliance with antituberculosis treatment: Predictors and consequences in New York City. Am J Med 1997;102:164-170.
Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574-579.
Knirsch CA, Jain NL, Pablos-Mendez A, Friedman C, Hripcsak G. Tuberculosis Detection and Monitoring by an Automated Clinical Decision Support System. Infect Control Hosp Epidemiol 1998;19 (2) 94-100.
Hripcsak G, Knirsch CA, Jain N, Stazesky RC, Pablos-Mendez A, Fulmer T. A health information network for managing inner-city Tuberculosis: Bridging clinical care, public health, and home care. Computers and Biomedical Research 1999 Feb;32 (1):67-76.
Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Méndez A. Neighborhood poverty and the resurgence of Tuberculosis in New York City, 1984 to 1992. Am J Public Health 2001 Sep;91(9):1487-93.
Mecaskey JW, Knirsch CA, Kumaresan JA, Cook JA. The possibility of eliminating blinding trachoma. Lancet Infect Dis. 2003 Nov;3(11):728-34.
Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006 Nov 15;43(10):1264-71.
Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother. 2007 Feb;51(2):651-6.
Knirsch C. Trachoma: ancient scourge, disease elimination, and future research.
Curr Infect Dis Rep. 2007 Jan;9(1):21-8.
El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The Effect of Azithromycin on Ivermectin Pharmacokinetics – A Population Pharmacokinetic Model Analysis. PLoS Negl Trop Dis. 2008 May 14;2(5):e236.
OFFICE INFORMATION:
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 Back to top
NAME: Wendy McGahee, MD
ACADEMIC TITLE:
Adjunct Instructor in Clinical Medicine
EDUCATION:
Long Island University, BS, 1985
Morehouse School of Medicine, MD, 1995
SPECIALTY: General infectious diseases, substance abuse
OFFICE INFORMATION:
St. Luke's–Roosevelt Hospital Center
Addiction Institute of New York
Clark 6–Detoxification Unit
1111 Amsterdam Avenue
New York, NY 10025
E-mail: Wme150@columbia.edu Back to top
 |
|
NAME: Michael Parry, MD
ACADEMIC TITLE:
Adjunct Professor of Clinical Medicine |
EDUCATION:
Yale University, BA, 1966
Columbia College of Physicians and Surgeons, MD, 1970
SPECIALTY: General infectious diseases, travel medicine
OFFICE INFORMATION:
Stamford Hospital
Shelburne Road and West Broad Street
P.O. Box 9317
Stamford, CT 06904
Tel: 203-325-7295
E-mail: MParry@stamhealth.org Back to top
|
